Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $1.7 million.

  • Entrada Therapeutics' Change in Accured Expenses rose 22.97% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 46.99%. This contributed to the annual value of $1.7 million for FY2024, which is 55.19% down from last year.
  • Per Entrada Therapeutics' latest filing, its Change in Accured Expenses stood at $1.7 million for FY2024, which was down 55.19% from $3.8 million recorded in FY2023.
  • Entrada Therapeutics' 5-year Change in Accured Expenses high stood at $4.0 million for FY2021, and its period low was $578,000 during FY2020.
  • In the last 3 years, Entrada Therapeutics' Change in Accured Expenses had a median value of $1.8 million in 2022 and averaged $2.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 585.47% in 2021, then tumbled by 55.53% in 2022.
  • Yearly analysis of 5 years shows Entrada Therapeutics' Change in Accured Expenses stood at $578,000 in 2020, then soared by 585.47% to $4.0 million in 2021, then plummeted by 55.53% to $1.8 million in 2022, then spiked by 116.35% to $3.8 million in 2023, then crashed by 55.19% to $1.7 million in 2024.